Charcot-marie-tooth Disease
Charcot-Marie-Tooth disease (CMT) is a genetic disorder that affects the peripheral nerves, causing muscle weakness and wasting in the lower legs, feet, hands and forearms. CMT affects more than 2.6 million people worldwide, with an estimated prevalence of 1 in 2500, making it the most common inherited disorder of the peripheral nervous system. CMT is caused by mutations in genes that regulate the structure and function of peripheral nerves or the myelin sheath that covers and protects them, leading to axonal degeneration or demyelination. This can result in a variety of symptoms, including foot drop, high arches, hammer toes, weakness or atrophy in the muscles of the legs, arms, and hands. Neurological research and therapy for CMT is focused on developing treatments that can prevent or slow down the progression of the disease. This includes gene therapy, stem cell transplantation, and pharmacological interventions that address the underlying molecular pathways involved in axonal degeneration or demyelination. Clinical trials are underway to test the safety and efficacy of investigational drugs that target myelin sheath repair, nerve regeneration, or immune modulation in CMT patients. In addition, researchers are exploring the potential of gene therapies that can deliver functional copies of the mutated genes or silence the expression of harmful genes that cause CMT. In summary, there are significant advances in scientific research to better understand the pathophysiology of CMT and developing effective therapies to manage the symptoms, prevent the progression and ultimately find the cure for this devastating disorder, for which there is currently no cure.
← Journal of Neurological Research And Therapy